Page last updated: 2024-09-04

canertinib and Invasiveness, Neoplasm

canertinib has been researched along with Invasiveness, Neoplasm in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bhargava, R; Chen, ZH; Hamilton, R; Liu, S; Luketich, JD; Luo, JH; Michalopoulos, GK; Monga, SP; Nalesnik, M; Nelson, JB; Pennathur, A; Tao, J; Tseng, G; Yu, YP	1
Bitran, JD; Burnett, D; Chiappori, AA; Eiseman, I; Ellis, PM; Hamm, JT; Lenehan, P; Lovalvo, J; Olson, S; Zinner, RG	1

Trials

1 trial(s) available for canertinib and Invasiveness, Neoplasm

Article	Year
A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2006, Volume: 1, Issue:9 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Evaluation Studies as Topic; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasm Invasiveness; Neoplasm Staging; Neutropenia; Odds Ratio; Paclitaxel; Patient Selection; Probability; Prognosis; Risk Assessment; Single-Blind Method; Survival Analysis; Treatment Outcome; United States	2006

Article

Year

A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2006, Volume: 1, Issue:9

Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Evaluation Studies as Topic; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasm Invasiveness; Neoplasm Staging; Neutropenia; Odds Ratio; Paclitaxel; Patient Selection; Probability; Prognosis; Risk Assessment; Single-Blind Method; Survival Analysis; Treatment Outcome; United States

2006

Other Studies

1 other study(ies) available for canertinib and Invasiveness, Neoplasm

Article	Year
MAN2A1-FER Fusion Gene Is Expressed by Human Liver and Other Tumor Types and Has Oncogenic Activity in Mice. Gastroenterology, 2017, Volume: 153, Issue:4 Topics: alpha-Mannosidase; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Crizotinib; Dose-Response Relationship, Drug; Enzyme Activation; ErbB Receptors; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Gene Fusion; Golgi Apparatus; Humans; Liver Neoplasms; Mice; Mice, Knockout; Mice, SCID; Morpholines; Neoplasm Invasiveness; Neoplasm Transplantation; NIH 3T3 Cells; Oncogene Proteins, Fusion; Oncogenes; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; PTEN Phosphohydrolase; Pyrazoles; Pyridines; RNA Interference; Time Factors; Transfection; Tumor Burden	2017

Article

Year

MAN2A1-FER Fusion Gene Is Expressed by Human Liver and Other Tumor Types and Has Oncogenic Activity in Mice.

Gastroenterology, 2017, Volume: 153, Issue:4

Topics: alpha-Mannosidase; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Crizotinib; Dose-Response Relationship, Drug; Enzyme Activation; ErbB Receptors; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Gene Fusion; Golgi Apparatus; Humans; Liver Neoplasms; Mice; Mice, Knockout; Mice, SCID; Morpholines; Neoplasm Invasiveness; Neoplasm Transplantation; NIH 3T3 Cells; Oncogene Proteins, Fusion; Oncogenes; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; PTEN Phosphohydrolase; Pyrazoles; Pyridines; RNA Interference; Time Factors; Transfection; Tumor Burden

2017